IP Library Granted Patent US 10,583,201
Granted Patent B2
US 10,583,201 · App. 15/518,183 · Granted Mar 10, 2020

Efficient delivery of therapeutic molecules in vitro and in vivo

Inventors: Zheng-Yi Chen (Somerville, MA); David Liu (Cambridge, MA)
Assignee: Massachusetts Eye and Ear Infirmary
A61K48/0033A61K9/0046A61K9/127A61K38/45A61K38/465A61K48/0075A61P27/16C12N9/1241C12N9/22C12N15/102C12N15/11C12N15/111C12Y207/07C12Y301/00A61K38/00C07K2319/00C12N2310/14C12N2310/20C12N2320/32
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,583,201
App. No.
15/518,183
Granted
Mar 10, 2020
Kind
B2
Abstract

A chimeric molecule of one or more proteins or peptides fused, complexed or linked to one or more anionic molecules. Efficient in vitro and in vivo delivery is attained by encapsulating these molecules in cationic lipids or cationic liposomes. Methods of treatment include the intracellular delivery of these molecules to a specific therapeutic target.

Claims (10)

1. A method of treating deafness in a patient in need thereof, wherein the patient has a mutation in a genetic locus comprising Pmca2, said method comprising: administering to an ear of the patient a therapeutically effective amount of a chimeric molecule comprising at least one gene editing agent and a short guide RNA (sgRNA), fused, complexed or linked to one or more anionic molecules, wherein the sgRNA is specific for Pmca2, wherein the at least one gene editing agent comprises Cre recombinases, CRISPR/Cas molecules, TALE transcriptional activators, Cas9 nucleases, nickases, thereby treating deafness.

2. The method of claim 1 , wherein the chimeric molecule is anionic and is encapsulated in a cationic lipid formulation.

3. The method of claim 1 , wherein the chimeric molecule targets one or more genetic loci associated with deafness in a patient and modulates expression of the Pmca2 genetic locus.

4. The method of claim 3 , wherein the chimeric molecule comprises a Cas9 nuclease.

5. The method of claim 4 , wherein the gene editing agents comprise nucleic acids.

6. The method of claim 1 , wherein the anionic molecules comprise: oligonucleotides.

7. The method of claim 6 , wherein the proteins or peptides comprise: genome or gene editing agents.

8. The method of claim 2 , wherein the cationic liposome encapsulated chimeric molecule is administered to a patient's inner ear.

9. The method of claim 1 , wherein the anionic molecule comprises any one or more sequences having a sequence identity of at least about 75% to sequences comprising SEQ ID NOS: 1 to 19.

10. The method of claim 9 , wherein the one or more sequences comprise at least one or more of SEQ ID NOS: 1 to 19.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 11, 2021
From: THOMPSON, DAVID B.; ZURIS, JOHN
To: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
Reel/Frame 057148/0734 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 24, 2017
From: LIU, DAVID R.
To: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
Reel/Frame 043934/0673 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 24, 2017
From: CHEN, ZHENG-YI
To: MASSACHUSETTS EYE AND EAR INFIRMARY
Reel/Frame 043934/0852 →
Continuity (2)
Provisional Application 62062628 · Oct 10, 2014
Related Publication 20170326254A1 · Nov 16, 2017
Cited By (18)
US 12,239,626 US 12,281,303 US 12,281,338 US 12,310,939 US 12,351,837 US 12,359,218 US 12,390,514 US 12,406,749 US 12,435,330 US 12,435,331 US 12,473,543 US 12,473,573 US 12,509,680 US 12,516,308 US 12,522,807 US 12,570,972 US 12,624,353 US 12,624,354